OmniGuide Surgical To Sponsor Endometriosis Awareness on The Balancing Act ® Airing on Lifetime Television® April 5th
<0> OmniGuideBrad Smith, 617-551-8420CFO </0>
OmniGuide, Inc., a commercial stage medical device company, is sponsoring a segment on The Balancing Act ® airing on Lifetime Television® dedicated to the awareness of endometriosis, available treatment options, and questions women should ask their doctor if they suspect they may be suffering from endometriosis.
Approximately 176 million females worldwide suffer from endometriosis with up to 8.5 million women in North America alone. This disease has a significant impact on a woman’s quality of life and as a result, the total associated costs of endometriosis are estimated to be a staggering $22 billion annually.
Featured guests on the program include: Dr. Charles Miller of The Advanced IVF Institute of Naperville, IL, Dr. Millie Behera of The Fertility Treatment Center of Scottsdale, Arizona, and Heather C. Guidone, Surgical Program Director, Center for Endometriosis Care. All three have deep experience in educating women about and treating endometriosis and will share their first-hand knowledge to help provide women and their families with the information they need to make more informed treatment decisions.
“Most women with endometriosis suffer pain and present symptoms up to a full decade prior to diagnosis,” said Scott Flora, President and CEO, OmniGuide. “OmniGuide is proud to be sponsoring this nationally televised segment in the hopes that it raises awareness of endometriosis and enables patients and their friends and family to have a more informed discussion with their doctor about the disease and the different treatment options available today.”
The segment with be featured on The Balancing Act® on Lifetime Television®, April 5 at 7 – 8 am ET/PT.
OmniGuide, Inc. is a leader in the development and marketing of advanced surgical energy solutions for minimally invasive surgery that improve precision, access and control. OmniGuide’s products are sold under the BeamPath® brand and are clinically targeted for superior clinical outcomes in Gynecology and ENT. The Company distributes its products in the U.S. through a direct sales force. OmniGuide is committed to developing products that improve and expand surgical treatment options, enhance clinical outcomes, and reduce treatment complexity and cost.
Additional information about OmniGuide may be found at .